Background: Hepatitis B virus (HBV) infection is a major cause of chronic liver disease and hepatocellular carcinoma. About a one third of the world's population is infected with the HBV. To control the spread of HBV it is important to understand the molecular epidemiology of HBV.
Introduction
Hepatitis B virus (HBV) infection is still an important public health problem. More than 350 million people worldwide have chronic hepatitis B (CHB). The serum HBV DNA level is an important marker of the viral activity. It is proved that a high viral load plays an important role in the development of CHB complications. A lower HBV DNA level is associated with a lower risk of a hepatocellular carcinoma (HCC) development than a higher level (Chan, 2012) .
The HBV DNA level varies considerably with time, so for dynamic observation the measurement must be repeated. However, the viral load measurement is an expensive method which requires specialized equipment. As a result in clinical practice HBV infected patients are being monitored with Hepatitis B e antigen (HBeAg) only which is an indicator of active viral replication. High viral load has been found to correlate significantly with HBeAg status (Maria et al., 2015; Parizad et al., 2016) . However there are reports that in many patients with pre core mutations HBeAg may be negative and patient may have high HBV DNA levels (Seeger et al 2007;  ., Taghavi et al., 2010) .
HBeAg-negative CHB is associated with the lower HBV DNA viral load, more significant intrahepatic necroinflammatory damage, more progressive disease and higher number of cirrhosis and/or hepatocellular carcinoma compared to HBeAg-positive CHB. HBeAg-negative HBV patients are more difficult to treat than HBeAg positive due to lower sustained responses (Pasdar et al., 2017) . the amount of cccDNA inside hepatocytes (Brunetto, 2010; Chan et al., 2010) .
Therefore, the present study was undertaken to investigate the correlation between the HBV DNA level and HBeAg status in patients attending SMS Hospital.Material and Methods
The present study was conducted on 100 HBsAg positive patients, whose blood samples were received for HBV DNA viral load in the Advance Research Laboratory in the Department of Microbiology and Immunology, SMS Medical College, Jaipur from different Wards and OPDs of SMS hospital and allied hospitals.
Biochemical estimation
Blood (plasma/serum): A total 5 mL of blood was collected in an EDTA (ethylene diamine tetra acetic acid) vial for PCR and in plain vial for serology. The blood was centrifuged and plasma/serum was transferred to a sterile eppendrof tube for storage. Samples were stored in freezer at -20 C till they were 0 tested. 
Results and discussion
Majority (48%) of the patients included in the present study were adults and most of the patients (60%) were found to be asymptomatic. Out of 100 patients, 80 (80%) were males and only 20 (20%) were females. Out of 100 samples 28 were HBeAg positive and 72 were HBeAg negative. Out of 100 patients, in 86% (86/100) the mode of transmission was unknown and majority of patients belonged to the asymptomatic group. The mode of transmission by HRSC, blood transfusion and perinatal route were 2%, 10% and 2% respectively (Table 1) .
Of above mentioned 28 HBeAg positive samples 16 (57.15%) were having viral load >20000 IU/mL and 12 (42.85%) were having viral load <20000 IU/mL. Out of 72 HBeAg negative samples 20 (27.77%) were having viral load >20000 IU/mL and 52 (72.23%) were having viral load <20000 IU/mL. In 26% (26/100) of the patients, the target was not in detectable/ very low (below 29 IU/ML) range and these all were HBeAg negative ( Table 2) .
In present study we studied correlation of serum HBeAg and HBV DNA levels as both are used biomarkers to monitor the disease course and response to treatment in HBV positive patients.
In present study, 82% of patients were adults. Similarly various studies have reported that adults men or older were most commonly affected with HBV (Attaullah et al., 2011; Karki et al., 2008) . The prevalence of HBV has been reported to be significantly elevated in males then females, similar findings have been reported from India (Chattopadhyay et al., 2006; Perumal et al., 2004; Attaullah et al., 2011) . This could be due to higher prevalence of infection in adult males as they are more exposed to the risk factors.
www.ajpp.in In present study we observed that the HBV DNA load was high in HBeAg positive cases, and good correlation was seen between the two, but in 26% of HBeAg negative cases the HBV DNA levels were > 20,000 IU/mL which is the level at which treatment is started, monitoring these patients only on basis of HBeAg can be misleading in such cases. Such findings are generally observed in patients with precore mutations (Ghabeshi et al., 2013) . Moreover 46 (62.16%) HBeAg negative patients had HBV DNA level more than 29 IU/mL. Therefore only HBeAg cannot be used as marker for monitoring CHB patients. However as in these patients HBeAg status was done only once, which can be misleading, it is recommended to do HBeAg testing at least twice to predict response of CHB patients. Another limitation of the study was that sequencing was not done to know the presence of precore mutations.
Certain studies have even used HBsAg quantitation by chemiluminescence, Architect QT (Abbott Laboratories) and Elecsys HBsAg II quant (Roche Diagnostics) to monitor response to treatment and correlate level with HBV DNA though some authors have reported contradicting results also, whether HBsAg and HBeAg detection correlates with HBV DNA (Kuhns et al., 2004; Wiegand et al., 2008) , but most studies have shown significant correlation between these values (Manesis et al., 2007; Moucari et al., 2009; Brunetto et al., 2009) .
Several studies show that HBsAg and HBV DNA levels change during different phases of CHB (Nguyen et al., 2010; Jaroszewicz et al., 2010; Chan et al., 2011) . Without treatment, the serum HBsAg level changes slower than the HBV DNA level (Chan et al., 2010; Nguyen et al., 2010) . Recently HBsAg level has been used for differentiating between inactive carriers and patients with active disease. Most inactive carriers of HBV infection have a low HBsAg level (Chan et al., 2010) .
There have been many limitations in our study, we had not done HBsAg quantitation by chemiluminescence which would have helped understand correlation of HBsAg HBeAg and HBV DNA levels, moreover sequencing of precore mutations would also help us understand the correlation better.
Conclusion
It's important to carry out HBV viral load testing in patients who are HBsAg positive on regular basis not only in HBeAg positive cases but in negative cases too. As in our study, we found that 26% HBeAg negative patients had viral load more than 20000 IU/mL which mandates initiation of treatment and only 26% patients had viral load below 6 IU/mL or TND in HBeAg cases. 
